Compare IDEXX Laboratories, Inc. (IDXX) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.3× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 3,211,044). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| IDXX | SJNK | |
|---|---|---|
Market Cap | $40.43B | $4.35B |
Volume | 692,164 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $25.57 |
52-Week Low | $504.70 | $24.13 |
Typical Hold Time | 46 Days | 41 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.20, down 0.21% with a bearish technical outlook. The ETF shows strong institutional interest despite recent selling activity by some firms. Dividend distributions remain consistent with recent payments of $0.14-$0.15 per share, providing income appeal in a rising rate environment.
The ETF faces headwinds from technical weakness but maintains income appeal through consistent dividends. Key risks include interest rate sensitivity and institutional selling pressure, while the current yield advantage over Treasuries presents opportunity for income-focused investors in the high-yield bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
